Not Medicare Enrolled

Dr. Todd Horiuchi, MD

Pulmonary Disease · Sarasota, FL
1875 FLOYD ST, Sarasota, FL 34239
9416676100
Registered in NPPES since 2006
NPI: 1609808161 verify on NPPES ↗
Moderate
DATA COVERAGE
Data in 2 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Horiuchi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Horiuchi? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Horiuchi

Dr. Todd Horiuchi is a pulmonary disease specialist in Sarasota, FL, with 20 years of NPI registration.

Between the years covered by Open Payments, Dr. Horiuchi received a total of $4,867 from 49 pharmaceutical and/or device companies across 235 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Horiuchi is Moderate — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years of NPI registration $4,867 industry payments

Florida License Status

FL DOH · MQA
1
Active license
None
Board action on record
0
Recent admin complaints
Profession License # Status Expires Board Action
Medical Doctor 83060 Clear January 31, 2028 —
Data from Florida Department of Health Medical Quality Assurance. License records are public under Chapter 119, Florida Statutes. Verify directly on FL DOH →

Industry Payment Transparency

Open Payments through 2024 ↗
$4,867
Total received (2018-2024)
Avg $695/year across 7 years
Top 37% in FL for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
49
Companies
235
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →

Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$112
2023
$433
2022
$227
2021
$229
2020
$902
2019
$1,505
2018
$1,460

Payments by company (2024)

Lilly USA, LLC
$71
SCPHARMACEUTICALS INC.
$24
Novartis Pharmaceuticals Corporation
$17
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$482
Actelion Pharmaceuticals US, Inc.
$408
GlaxoSmithKline, LLC.
$313
Novo Nordisk Inc
$272
Boehringer Ingelheim Pharmaceuticals, Inc.
$235
Takeda Pharmaceuticals U.S.A., Inc.
$223
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$203
PFIZER INC.
$177
TETRAPHASE PHARMACEUTICALS, INC.
$150
Janssen Pharmaceuticals, Inc
$146
AstraZeneca Pharmaceuticals LP
$138
United Therapeutics Corporation
$125
Alexion Pharmaceuticals, Inc.
$122
JAZZ PHARMACEUTICALS INC.
$121
Genentech USA, Inc.
$119
Auris Health, Inc.
$117
Bayer HealthCare Pharmaceuticals Inc.
$117
Philips Electronics North America Corporation
$112
Regeneron Healthcare Solutions, Inc.
$107
Allergan Inc.
$95
Shire North American Group Inc
$94
Lilly USA, LLC
$90
Radius Health, Inc.
$74
PORTOLA PHARMACEUTICALS, INC.
$72
Mallinckrodt LLC
$69
Astellas Pharma US Inc
$51
Antares Pharma, Inc.
$49
Avanir Pharmaceuticals, Inc.
$44
SANOFI-AVENTIS U.S. LLC
$44
Circassia Pharmaceuticals Inc
$43
Jazz Pharmaceuticals Inc.
$39
Aytu BioScience, Inc
$38
AbbVie, Inc.
$37
Bayer Healthcare Pharmaceuticals Inc.
$35
Paratek Pharmaceuticals, Inc.
$33
IBSA Pharma Inc.
$32
SCPHARMACEUTICALS INC.
$24
Gilead Sciences, Inc.
$23
BOSTON SCIENTIFIC CORPORATION
$21
OptiNose US, Inc.
$20
AbbVie Inc.
$20
SANOFI PASTEUR INC.
$20
Sunovion Pharmaceuticals Inc.
$19
Novartis Pharmaceuticals Corporation
$17
Allergan, Inc.
$17
Chiesi USA, Inc.
$16
Insmed, Inc.
$15
Advanced Respiratory, Inc
$14
IDORSIA PHARMACEUTICALS US INC
$13
Top 3 companies account for 24.7% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · ANORO · Adempas · Aimovig · Andexxa · BEVYXXA · BREO · BYSTOLIC · CHANTIX · CLEVIPREX · CUVITRU · Creon · ELIQUIS · EVENITY · FLUBLOK QUADRIVALENT · FUROSCIX · GLASSIA · HYQVIA · JARDIANCE · Kerendia · LEQVIO · LINZESS · LONHALA MAGNAIR · MYRBETRIQ · NUCALA · NUEDEXTA · NUZYRA · Natesto · OFEV · OFIRMEV · OPSUMIT · OPSUMIT MACITENTAN · Otrexup · Ozempic · PRADAXA · PRALUENT · PRALUENT ALIROCUMAB INJECTION · QUVIVIQ · Repatha · SHINGRIX · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · Saxenda · Synthroid · TEZSPIRE · TRELEGY ELLIPTA · TRINTELLIX · TRULICITY · TUDORZA PRESSAIR · TYVASO · The Vest System Model 105 Home Care · Tirosint · Tresiba · Trilogy 100 · Trintellix · Tuzistra XR · Tymlos · UPTRAVI · VIIBRYD · VRAYLAR · Victoza · WATCHMAN · XARELTO · XIFAXAN · XYOSTED · XYWAV · Xerava · Xhance · Xofluza · Xolair · inCourage
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Looking for a pulmonary disease specialist in Sarasota?
Compare pulmonary diseases in the Sarasota area by procedure volume, costs, and industry payment transparency.
Browse pulmonary diseases nearby

Geographic Context

Pulmonary diseases in nearby ZIP areas
31
County median income
$80,633
Nearest hospital to ZIP centroid (approximate)
SARASOTA MEMORIAL HOSPITAL
0.0 mi

Data Sources

Provider Registry ✓ NPPES NPPES snapshot; verify current record
Medicare Enrollment — Not enrolled N/A
Practice Data — No data N/A
Industry Payments ✓ Open Payments CY 2024
Disciplinary History — Not included N/A

This provider has data in 2 of 4 available federal datasets, with a Data Coverage level of Moderate. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Horiuchi is a pulmonary disease specialist, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Does Dr. Horiuchi receive payments from pharmaceutical companies?
Yes. Dr. Horiuchi received a total of $4,867 from 49 companies across 235 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently Moderate for Dr. Horiuchi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →

Explore related providers

Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Sarasota
Browse pulmonary diseases in Sarasota ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in FL
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in FL
Which FL pulmonary diseases receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Actelion Pharmaceuticals US, Inc. Payments to Doctors
See all physicians who received payments from Actelion Pharmaceuticals US, Inc.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
About this page

This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Industry payment disclosure alone establishes neither wrongdoing nor legality. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →